72 related articles for article (PubMed ID: 22672156)
1. Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers.
Homey B; Gerber PA; Wollenberg A; Dirschka T; Hassel JC; Bölke E; Hauschild A; Gutzmer R
J Dtsch Dermatol Ges; 2012 Aug; 10(8):559-63. PubMed ID: 22672156
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous side-effects of EGFR inhibitors and their management.
Ehmann LM; Ruzicka T; Wollenberg A
Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
[TBL] [Abstract][Full Text] [Related]
3. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
[TBL] [Abstract][Full Text] [Related]
4. New drug therapies and their effect on the skin.
Treudler R
J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
[TBL] [Abstract][Full Text] [Related]
5. General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption.
Farahnik B; Kwong B; Murase J
J Am Acad Dermatol; 2016 Nov; 75(5):e191. PubMed ID: 27745649
[No Abstract] [Full Text] [Related]
6. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
8. Manage skin toxicities associated with EGFR inhibitors.
Becze E
ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873
[No Abstract] [Full Text] [Related]
9. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
10. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
LoRusso P
Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
[TBL] [Abstract][Full Text] [Related]
11. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
12. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
15. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
Iacovelli L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
[TBL] [Abstract][Full Text] [Related]
18. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of EGFRI dermatologic toxicities: the nursing perspective.
Purdom M; Ohinata A
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):29-30. PubMed ID: 18154215
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
